Bio News
Netherlands-based biopharmaceutical company Byondis has appointed Dr. Christoph Kopus as its new chief executive officer (CEO). Kopus has more than 15 years of experience in oncology research and development and will lead R&D for the next-generation antibody-drug conjugate (ADC) technology platform, which combines proprietary payload and linker technologies, including the ByonZ™ masking technology. Byondis, which has more than 200 employees, plans to pursue technology licensing and co-development opportunities for pipeline assets, supported by its in-house GMP manufacturing facilities.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
